Acadian Asset Management LLC raised its holdings in shares of Affimed NV (NASDAQ:AFMD) by 3,524.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,176,604 shares of the biopharmaceutical company’s stock after acquiring an additional 2,116,546 shares during the quarter. Acadian Asset Management LLC owned approximately 3.49% of Affimed worth $6,247,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of the company. GSA Capital Partners LLP bought a new position in shares of Affimed in the second quarter worth $478,000. CIBC World Markets Inc. increased its position in shares of Affimed by 17.7% in the first quarter. CIBC World Markets Inc. now owns 66,500 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 10,000 shares during the period. Geode Capital Management LLC increased its position in shares of Affimed by 29.0% in the fourth quarter. Geode Capital Management LLC now owns 66,074 shares of the biopharmaceutical company’s stock worth $205,000 after purchasing an additional 14,854 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Affimed in the second quarter worth $169,000. Finally, MYDA Advisors LLC grew its position in Affimed by 150.0% in the first quarter. MYDA Advisors LLC now owns 50,000 shares of the biopharmaceutical company’s stock valued at $210,000 after acquiring an additional 30,000 shares during the last quarter. 46.69% of the stock is owned by institutional investors.
A number of research analysts have issued reports on AFMD shares. Zacks Investment Research cut Affimed from a “buy” rating to a “hold” rating in a research report on Thursday, August 8th. ValuEngine raised Affimed from a “sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Finally, Laidlaw set a $10.00 price target on Affimed and gave the company a “buy” rating in a research note on Wednesday, July 3rd. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Affimed presently has a consensus rating of “Buy” and an average price target of $6.08.
Shares of AFMD opened at $2.84 on Friday. Affimed NV has a 52-week low of $2.52 and a 52-week high of $5.30. The business’s 50 day moving average price is $2.84 and its two-hundred day moving average price is $3.29. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.48 and a quick ratio of 3.47.
Affimed (NASDAQ:AFMD) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.16). Affimed had a negative return on equity of 30.94% and a negative net margin of 30.87%. The firm had revenue of $4.50 million during the quarter, compared to the consensus estimate of $6.46 million. As a group, research analysts forecast that Affimed NV will post -0.31 earnings per share for the current fiscal year.
Affimed Company Profile
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, a natural killer cell (NK-cell) TandAb, which is in Phase 2a clinical study of relapsed CD30-positive lymphoma and Phase 1b clinical study of anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed Hodgkin lymphoma.
Read More: What is a Market Correction?
Receive News & Ratings for Affimed Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Affimed and related companies with MarketBeat.com’s FREE daily email newsletter.